Spots Global Cancer Trial Database for lifileucel
Every month we try and update this database with for lifileucel cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | NCT03645928 | Metastatic Mela... Squamous Cell C... Non-small Cell ... | Lifileucel LN-145 Pembrolizumab LN-145-S1 Ipilimumab Nivolumab | 12 Years - | Iovance Biotherapeutics, Inc. | |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | NCT05361174 | Unresectable Me... Metastatic Mela... Stage III Non-s... Stage IV Non-sm... | IOV-4001 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma | NCT06151847 | Clinical Stage ... Metastatic Mela... Pathologic Stag... Unresectable Me... | Biospecimen Col... Cyclophosphamid... Echocardiograph... Fludarabine Interleukin-2 Lifileucel Magnetic Resona... Multigated Acqu... Tumor Resection | 18 Years - 70 Years | University of Kansas Medical Center | |
| Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma | NCT02360579 | Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | NCT03645928 | Metastatic Mela... Squamous Cell C... Non-small Cell ... | Lifileucel LN-145 Pembrolizumab LN-145-S1 Ipilimumab Nivolumab | 12 Years - | Iovance Biotherapeutics, Inc. | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients | NCT05176470 | Locally Advance... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage IV Melano... | Cyclophosphamid... Fludarabine Lifileucel Pembrolizumab Therapeutic Con... | 18 Years - 75 Years | Ohio State University Comprehensive Cancer Center | |
| Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma | NCT02360579 | Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
